Nuvectis Pharma Inc. (NVCT) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Nuvectis Pharma Inc. (NASDAQ: NVCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $18.57 (+1.14% 1D, market cap $605.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NVCT ranks #546 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NVCT carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GERN (Geron Corporation) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.2%, cap $607.9M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C+ grade (69/100 RQD, P/E 24.9x, ROIC 85.0%, cap $598.2M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).
Per NVCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001875558), Nuvectis Pharma Inc. generated $0 in revenue, -$26.4M in net income, and -$16.0M in free cash flow against $31.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 55% of 52W Range • RSI-14 at 41.3 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While NVCT currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.45) and Max Pain ($19.50) forces dealer call-delta covering toward $30.74.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Nuvectis Pharma Inc. (NVCT) advanced +1.14% to $18.57, trading at 55% of its 52-week range ($5.55 – $29.28). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Single-agent NXP200 was administered to 27 patients with recurrent or progressive gliomas (20 with high-grade and 7 with low-grade).The objective response rate (ORR) based on Response Assessment in Neuro-Oncology criteri
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NVCT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NVCT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Nuvectis Pharma Inc. (NVCT) ranks #546 by composite RQD confidence (43/100, grade D-) and #419 by equity capitalization ($605.6M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with NVCT at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NVCT
ACTIVE
Nuvectis Pharma Inc. | D- | 43/100 | — | — | -35.0% | +1.14% | $605.6M | Benchmark Subject |
| GERN Geron Corporation | D- | 37/100 | — | — | -20.2% | -2.30% | $607.9M | /gern-vs-nvct → |
| IRWD Ironwood Pharmaceuticals Inc. (Class A) | C+ | 69/100 | 24.9x | — | 85.0% | +0.28% | $598.2M | /irwd-vs-nvct → |
| ZVRA Zevra Therapeutics Inc. | D- | 40/100 | 7.4x | — | -32.3% | +0.49% | $615.2M | /zvra-vs-nvct → |
| CRMD CorMedix Inc. | C | 62/100 | 3.7x | 88.5% | 45.5% | -6.83% | $595.5M | /crmd-vs-nvct → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nuvectis Pharma Inc. (NVCT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.4M, operating cash flow of -$16.0M, and free cash flow of -$16.0M (-30.7% YoY). On the balance sheet, NVCT closed FY2025 with $31.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$26.4M | -$16.0M | -$16.0M | $31.7M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$19.0M | -$12.2M | -$12.2M | $18.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$22.3M | -$16.0M | -$16.0M | — | — |
As of 2026-11-01, Nuvectis Pharma Inc. (NASDAQ: NVCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $18.57 (+1.14% 1D, market cap $605.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NVCT ranks #546 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NVCT carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GERN (Geron Corporation) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.2%, cap $607.9M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C+ grade (69/100 RQD, P/E 24.9x, ROIC 85.0%, cap $598.2M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).
Per NVCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001875558), Nuvectis Pharma Inc. generated $0 in revenue, -$26.4M in net income, and -$16.0M in free cash flow against $31.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NVCT last traded at $18.57 (+1.14% on volume of 117,692 shares), positioning the stock -13.43% below its 50-day simple moving average ($21.45) and +27.10% above its 200-day simple moving average ($14.61). Across its 52-week range of $5.55 to $29.28, NVCT sits at the 54.9% percentile with a 14-day RSI of 41.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($16.25 to $20.89).
Why NVCT Stock advanced +1.14% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.